Biotechnology company focused on developing gene therapies for rare diseases.
LogicBio Therapeutics, Inc., headquartered in Lexington, Massachusetts, is a pioneering genetic medicine company dedicated to advancing genome editing and gene therapy treatments through its innovative platforms, GeneRide and sAAVy. The GeneRide technology represents a novel approach to precise gene insertion, leveraging the natural DNA repair mechanisms within cells. Complementing this, the sAAVy platform utilizes adeno-associated virus vectors optimized for efficient gene delivery across various tissues and indications.
At the forefront of its pipeline is LB-001, the company's lead product candidate currently undergoing Phase I/II clinical trials for the treatment of methylmalonic acidemia, a rare genetic disorder. LogicBio Therapeutics has forged strategic collaborations to bolster its research capabilities, including partnerships with the Children's Medical Research Institute to develop advanced capsids for gene therapy applications in the liver and other tissues. Additionally, a collaboration with Takeda Pharmaceutical Company Limited focuses on advancing LB-301, an investigational therapy for Crigler-Najjar syndrome.
Founded in 2014, LogicBio Therapeutics has expanded its global footprint through collaborations such as those with CANbridge Care Pharma Hong Kong Limited and Daiichi Sankyo Company, enhancing its capabilities in genetic medicine. As of November 15, 2022, the company operates as a subsidiary of Alexion Pharmaceuticals, Inc., further strengthening its position in developing transformative therapies for genetic disorders.